Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Going Concern - Additional Information (Detail)

v3.7.0.1
Liquidity and Going Concern - Additional Information (Detail) - USD ($)
Jul. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Liquidity and Going Concern [Line Items]      
Cash   $ 50,325,193 $ 29,355,528
Subsequent Event [Member] | AstraZeneca [Member]      
Liquidity and Going Concern [Line Items]      
Amount funded by collaborative partner $ 45,000,000